Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy-MedSci.cn

Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

Paulus, A; Manna, A; Wang, HB; Chen, JY; Min, P; Yin, Y; Dutta, N; Halder, N; Ciccio, G; Copland, J; Han, B; Bai, LC; Liu, L; Wang, M; McEachern, D; Przybranowski, S; Yang, CY; Stuckey, J; Wu, DP; Li, CX; Ryan, J; Letai, A; Ailawadhi, S; Yang, DJ; Wang, SM; Chanan-Khan, A; Zhai, YF

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

科室

工具

服务